210 related articles for article (PubMed ID: 30446740)
1. Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs.
Gowda L; Shah M; Badar I; Bashir Q; Shah N; Patel K; Kanagal-Shamanna R; Mehta R; Weber DM; Lee HC; Manasanch EE; Shah A; Thomas SK; Parmar S; Nieto Y; Orlowski RZ; Champlin R; Qazilbash MH
Bone Marrow Transplant; 2019 Jul; 54(7):1089-1093. PubMed ID: 30446740
[TBL] [Abstract][Full Text] [Related]
2. Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents.
Mina R; Joseph NS; Kaufman JL; Gupta VA; Heffner LT; Hofmeister CC; Boise LH; Dhodapkar MV; Gleason C; Nooka AK; Lonial S
Cancer; 2019 Feb; 125(3):416-423. PubMed ID: 30332496
[TBL] [Abstract][Full Text] [Related]
3. Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group.
Katodritou E; Terpos E; Delimpasi S; Kotsopoulou M; Michalis E; Vadikolia C; Kyrtsonis MC; Symeonidis A; Giannakoulas N; Vadikolia C; Michael M; Kalpadakis C; Gougopoulou T; Prokopiou C; Kaiafa G; Christoulas D; Gavriatopoulou M; Giannopoulou E; Labropoulou V; Verrou E; Kastritis E; Konstantinidou P; Anagnostopoulos A; Dimopoulos MA
Blood Cancer J; 2018 Mar; 8(3):31. PubMed ID: 29523783
[TBL] [Abstract][Full Text] [Related]
4. Primary Plasma Cell Leukemia in the Era of Novel Agents: A Multicenter Study of the Japanese Society of Myeloma.
Iriuchishima H; Ozaki S; Konishi J; Matsumoto M; Murayama K; Nakamura F; Yamamoto G; Handa H; Saitoh T; Nagura E; Shimizu K; Nojima Y; Murakami H
Acta Haematol; 2016; 135(2):113-21. PubMed ID: 26505781
[TBL] [Abstract][Full Text] [Related]
5. Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients.
Jurczyszyn A; Radocha J; Davila J; Fiala MA; Gozzetti A; Grząśko N; Robak P; Hus I; Waszczuk-Gajda A; Guzicka-Kazimierczak R; Atilla E; Mele G; Sawicki W; Jayabalan DS; Charliński G; Szabo AG; Hajek R; Delforge M; Kopacz A; Fantl D; Waage A; Avivi I; Rodzaj M; Leleu X; Richez V; Knopińska-Posłuszny W; Masternak A; Yee AJ; Barchnicka A; Druzd-Sitek A; Guerrero-Garcia T; Liu J; Vesole DH; Castillo JJ
Br J Haematol; 2018 Mar; 180(6):831-839. PubMed ID: 29315478
[TBL] [Abstract][Full Text] [Related]
6. Primary Plasma Cell Leukemia: Identity Card 2016.
Musto P; Simeon V; Todoerti K; Neri A
Curr Treat Options Oncol; 2016 Apr; 17(4):19. PubMed ID: 26995215
[TBL] [Abstract][Full Text] [Related]
7. Trends in survival of patients with primary plasma cell leukemia: a population-based analysis.
Gonsalves WI; Rajkumar SV; Go RS; Dispenzieri A; Gupta V; Singh PP; Buadi FK; Lacy MQ; Kapoor P; Dingli D; Lust JA; Zeldenrust SR; Hayman SR; Kyle RA; Gertz MA; Kumar SK
Blood; 2014 Aug; 124(6):907-12. PubMed ID: 24957143
[TBL] [Abstract][Full Text] [Related]
8. [The clinical characteristics of patients with primary plasma cell leukemia and the efficacy of novel agents and hematopoietic stem cell transplantation].
Li WJ; Wang FR; Wen L; Chen Y; Chen H; Huang XJ; Lu J
Zhonghua Nei Ke Za Zhi; 2020 Oct; 59(10):801-806. PubMed ID: 32987483
[No Abstract] [Full Text] [Related]
9. Primary plasma cell leukemia: report of 17 new cases treated with autologous or allogeneic stem-cell transplantation and review of the literature.
Saccaro S; Fonseca R; Veillon DM; Cotelingam J; Nordberg ML; Bredeson C; Glass J; Munker R
Am J Hematol; 2005 Apr; 78(4):288-94. PubMed ID: 15795922
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome.
Royer B; Minvielle S; Diouf M; Roussel M; Karlin L; Hulin C; Arnulf B; Macro M; Cailleres S; Brion A; Brechignac S; Belhadj K; Chretien ML; Wetterwald M; Chaleteix C; Tiab M; Leleu X; Frenzel L; Garderet L; Choquet S; Fuzibet JG; Dauriac C; Forneker LM; Benboubker L; Facon T; Moreau P; Avet-Loiseau H; Marolleau JP
J Clin Oncol; 2016 Jun; 34(18):2125-32. PubMed ID: 27114594
[TBL] [Abstract][Full Text] [Related]
11. Treatment of primary plasma cell leukemia with high doses of cyclophosphamide, bortezomib, and dexamethasone followed by double autologous HSCT.
Pagano L; Maraglino AME; Fianchi L; Criscuolo M; Rossi E; Za T; Chiusolo P; Bonanni M; Dragonetti G; Bacigalupo A; Sica S; De Stefano V
Ann Hematol; 2020 Jan; 99(1):207-209. PubMed ID: 31832752
[No Abstract] [Full Text] [Related]
12. An update on biology, diagnosis and treatment of primary plasma cell leukemia.
Musto P; Statuto T; Valvano L; Grieco V; Nozza F; Vona G; Bochicchio GB; La Rocca F; D'Auria F
Expert Rev Hematol; 2019 Apr; 12(4):245-253. PubMed ID: 30905220
[TBL] [Abstract][Full Text] [Related]
13. Clinical Characteristics and Outcomes of Patients With Primary Plasma Cell Leukemia in the Era of Novel Agent Therapy.
Nandakumar B; Kumar SK; Dispenzieri A; Buadi FK; Dingli D; Lacy MQ; Hayman SR; Kapoor P; Leung N; Fonder A; Hobbs M; Hwa YL; Muchtar E; Warsame R; Kourelis TV; Russell S; Lust JA; Lin Y; Siddiqui M; Go RS; Jevremovic D; Kyle RA; Gertz MA; Rajkumar SV; Gonsalves WI
Mayo Clin Proc; 2021 Mar; 96(3):677-687. PubMed ID: 33673918
[TBL] [Abstract][Full Text] [Related]
14. Primary Plasma Cell Leukemia: Real-World Retrospective Study of 46 Patients From a Single-Center Study in China.
Yu T; Xu Y; An G; Tai YT; Ho M; Li Z; Deng S; Zou D; Yu Z; Hao M; Anderson KC; Qiu L
Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e652-e659. PubMed ID: 32624447
[TBL] [Abstract][Full Text] [Related]
15. Plasma cell leukemia: from biology to treatment.
Jelinek T; Kryukov F; Rihova L; Hajek R
Eur J Haematol; 2015 Jul; 95(1):16-26. PubMed ID: 25778450
[TBL] [Abstract][Full Text] [Related]
16. Primary plasma cell leukemia 2.0: advances in biology and clinical management.
Neri A; Todoerti K; Lionetti M; Simeon V; Barbieri M; Nozza F; Vona G; Pompa A; Baldini L; Musto P
Expert Rev Hematol; 2016 Nov; 9(11):1063-1073. PubMed ID: 27759436
[TBL] [Abstract][Full Text] [Related]
17. Primary plasma cell leukemia in the era of novel agents for myeloma - a multicenter retrospective analysis of outcome.
Ganzel C; Rouvio O; Avivi I; Magen H; Jarchowsky O; Herzog K; Cohen Y; Tadmor T; Horwitz NA; Leiba M; Nagler A; Cohen Y; Bulvik S; Polliack A; Rowe JM; Gatt ME;
Leuk Res; 2018 May; 68():9-14. PubMed ID: 29501828
[TBL] [Abstract][Full Text] [Related]
18. A clinical perspective on plasma cell leukemia; current status and future directions.
Tuazon SA; Holmberg LA; Nadeem O; Richardson PG
Blood Cancer J; 2021 Feb; 11(2):23. PubMed ID: 33563906
[TBL] [Abstract][Full Text] [Related]
19. Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party.
D'Arena G; Valentini CG; Pietrantuono G; Guariglia R; Martorelli MC; Mansueto G; Villani O; Onofrillo D; Falcone A; Specchia G; Semenzato G; Di Renzo N; Mastrullo L; Venditti A; Ferrara F; Palumbo A; Pagano L; Musto P
Ann Oncol; 2012 Jun; 23(6):1499-502. PubMed ID: 22039089
[TBL] [Abstract][Full Text] [Related]
20. Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival.
Htut M; D'Souza A; Krishnan A; Bruno B; Zhang MJ; Fei M; Diaz MA; Copelan E; Ganguly S; Hamadani M; Kharfan-Dabaja M; Lazarus H; Lee C; Meehan K; Nishihori T; Saad A; Seo S; Ramanathan M; Usmani SZ; Gasparetto C; Mark TM; Nieto Y; Hari P
Biol Blood Marrow Transplant; 2018 Mar; 24(3):478-485. PubMed ID: 29079457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
